Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells

I would like to comment on a recent article published in the European Journal of Cancer by Guanhua Rao et  al., who described a very interesting synergistic combination of dasatinib and trametinib in KRAS-dependent cancer cells [1]. According to their data, dasatinib sensitises KRAS-mutant cells to MEK inhibition via suppression of SRC kinases and downregulation of the YAP/TAZ signalling pathway.

Source: European Journal of Cancer - October 12, 2018 Category: Cancer & Oncology Authors: Luca Mologni Tags: Letter to the Editor Source Type: research